BridgeBio PharmaFRA:2CL -0.61%66 Days Payable is 297.59 as of Mar. 2026, which is 76% below its 10-year median of 1,233.27. GuruFocus rates FRA:2CL with a GF Score™ of 66/100 and a GF Value™ of €122.43 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 706 Biotechnology companies, BridgeBio Pharma ranks better than 73.8% on this metric.
The historical rank and industry rank for BridgeBio Pharma's Days Payable or its related term are showing as below:
FRA:2CL'
s Days Payable Range Over the Past 10 Years
Min: 355.54 Med: 1233.27 Max: 1657.35
Current: 355.54
During the past 9 years, BridgeBio Pharma's highest Days Payable was 1657.35. The lowest was 355.54. And the median was 1233.27.
FRA:2CL's Days Payable is ranked better than 73.8% of 706
companies
in the Biotechnology industry
Industry Median: 113.56
vs FRA:2CL: 355.54
BridgeBio Pharma's Days Payable
declined
from Mar. 2025 (647.31) to Mar. 2026 (297.59).
It may suggest that BridgeBio Pharmaaccelerated paying its suppliers.
BridgeBio Pharma Days Payable Related Terms
BridgeBio Pharma Days Payable Historical Data
* Premium members only.
The historical data trend for BridgeBio Pharma's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2CL vs EXEL, IONS, SMMT: Days Payable Comparison
For the Biotechnology subindustry, BridgeBio Pharma's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BridgeBio Pharma Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Days Payable distribution charts can be found below:
* The bar in red indicates where BridgeBio Pharma's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BridgeBio Pharma's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BridgeBio Pharma (FRA:2CL) has a Days Payable of 297.59 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BridgeBio Pharma and its competitors. This is 76% below median its historical median of 1,233.27. Over the past decade, BridgeBio Pharma's Days Payable has ranged from 355.54 to 1,657.35. According to the industry distribution chart, BridgeBio Pharma ranks #185 out of 706 companies in the Biotechnology industry, placing it in the top 26.2%.
Is BridgeBio Pharma's Days Payable too high?
BridgeBio Pharma's current Days Payable of 297.59 is 76% below median its 10-year median of 1,233.27. Over the past 10 years, this metric has ranged from a low of 355.54 to a high of 1,657.35. The Biotechnology industry median Days Payable is 113.56. BridgeBio Pharma's value of 297.59 is 162.1% above this industry median. Based on the distribution chart, BridgeBio Pharma ranks #185 out of 706 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BridgeBio Pharma has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Days Payable compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #185 out of 706 companies for Days Payable. This puts BridgeBio Pharma in the upper half of its industry. The industry median Days Payable is 113.56. BridgeBio Pharma's value of 297.59 is 162.1% above this benchmark. Historically, BridgeBio Pharma's own Days Payable has ranged from 355.54 to 1,657.35 over the past decade. While the company's 10-year median is 1,233.27 vs. the industry median of 113.56, BridgeBio Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Pharma's current Days Payable of 297.59 is 162.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BridgeBio Pharma and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current Days Payable is 297.59, which is 76% below median its own 10-year median of 1,233.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €122.43, compared to a current price of €59.93 — trading 51% below its estimated fair value. The current Days Payable is 297.59, which is 76% below median its 10-year median of 1,233.27 and 162.1% above the Biotechnology industry median of 113.56. BridgeBio Pharma's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Days Payable is 297.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?
Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued.
The current stock price of €59.93 is trading 51% below its estimated GF Value™ of €122.43.
GuruFocus considers BridgeBio Pharma to be Possible Value Trap.
Key valuation signals for FRA:2CL:
Days Payable: 297.59 (76% below median its 10-year median of 1,233.27)
GF Value™: €122.43 vs. price of €59.93 (51% below fair value)
Industry Position: 162.1% above the Biotechnology median (#185 of 706)
No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
66GF Score
Get the complete analysis for FRA:2CL
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2CL has been successfully added to your 
